Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?

Research output: Contribution to journal › Review › Research › peer-review

Standard

Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists : Could this work and how? / Smits, Mark M.; Holst, Jens J.

In: Diabetes/Metabolism Research and Reviews, Vol. 39, No. 8, e3699, 2023.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Smits, MM & Holst, JJ 2023, 'Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?', Diabetes/Metabolism Research and Reviews, vol. 39, no. 8, e3699. https://doi.org/10.1002/dmrr.3699

APA

Smits, M. M., & Holst, J. J. (2023). Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how? Diabetes/Metabolism Research and Reviews, 39(8), [e3699]. https://doi.org/10.1002/dmrr.3699

Vancouver

Smits MM, Holst JJ. Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how? Diabetes/Metabolism Research and Reviews. 2023;39(8). e3699. https://doi.org/10.1002/dmrr.3699

Author

Smits, Mark M. ; Holst, Jens J. / Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists : Could this work and how?. In: Diabetes/Metabolism Research and Reviews. 2023 ; Vol. 39, No. 8.

Bibtex

@article{ac65711d35304212bff08d3e8ed2c02c,
title = "Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?",
abstract = "In recent years, we have witnessed the many beneficial effects of glucagon-like peptide (GLP)-1 receptor agonists, including the reduction in cardiovascular risk in patients with type 2 diabetes, and the reduction of body weight in those with obesity. Increasing evidence suggests that these agents differ considerably from endogenous GLP-1 when it comes to their routes of action, although their clinical effects appear to be the same. Given the limitations of the GLP-1 receptor agonists, could it be useful to develop agents which stimulate GLP-1 release? Here we will discuss the differences and similarities between GLP-1 receptor agonists and endogenous GLP-1, and will detail how endogenous GLP-1—when stimulated appropriately—could have clinically relevant effects.",
keywords = "diabetes, glucagon-like peptide-1, gut hormone, obesity",
author = "Smits, {Mark M.} and Holst, {Jens J.}",
note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.",
year = "2023",
doi = "10.1002/dmrr.3699",
language = "English",
volume = "39",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "JohnWiley & Sons Ltd.",
number = "8",

}

RIS

TY - JOUR

T1 - Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists

T2 - Could this work and how?

AU - Smits, Mark M.

AU - Holst, Jens J.

N1 - Publisher Copyright: © 2023 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.

PY - 2023

Y1 - 2023

N2 - In recent years, we have witnessed the many beneficial effects of glucagon-like peptide (GLP)-1 receptor agonists, including the reduction in cardiovascular risk in patients with type 2 diabetes, and the reduction of body weight in those with obesity. Increasing evidence suggests that these agents differ considerably from endogenous GLP-1 when it comes to their routes of action, although their clinical effects appear to be the same. Given the limitations of the GLP-1 receptor agonists, could it be useful to develop agents which stimulate GLP-1 release? Here we will discuss the differences and similarities between GLP-1 receptor agonists and endogenous GLP-1, and will detail how endogenous GLP-1—when stimulated appropriately—could have clinically relevant effects.

AB - In recent years, we have witnessed the many beneficial effects of glucagon-like peptide (GLP)-1 receptor agonists, including the reduction in cardiovascular risk in patients with type 2 diabetes, and the reduction of body weight in those with obesity. Increasing evidence suggests that these agents differ considerably from endogenous GLP-1 when it comes to their routes of action, although their clinical effects appear to be the same. Given the limitations of the GLP-1 receptor agonists, could it be useful to develop agents which stimulate GLP-1 release? Here we will discuss the differences and similarities between GLP-1 receptor agonists and endogenous GLP-1, and will detail how endogenous GLP-1—when stimulated appropriately—could have clinically relevant effects.

KW - diabetes

KW - glucagon-like peptide-1

KW - gut hormone

KW - obesity

U2 - 10.1002/dmrr.3699

DO - 10.1002/dmrr.3699

M3 - Review

C2 - 37485788

AN - SCOPUS:85165442315

VL - 39

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

IS - 8

M1 - e3699

ER -

ID: 360860975